Kailera Plans IPO for Obesity Drug That Could Top Lilly’s Zepbound

Frank Vinluan / medcitynews - Kailera Therapeutics’ planned IPO will fund ongoing clinical development of a pipeline led by a drug that could rival Eli Lilly’s Zepbound in both efficacy and tolerability. Meanwhile, Renaissance Capital’s recap of first quarter 2026 IPOs shows slowing a…

AI Summary: Kailera announced plans for an initial public offering to fund late‑stage development of a Phase 3 obesity candidate licensed from Hengrui, positioning the program as a potential rival to Lilly’s Zepbound. The IPO aims to accelerate clinical work and commercial readiness as investors weigh market appetite for next‑generation weight‑loss therapies.


Antimicrobial resistance risk found in South African wastewater

Antimicrobial resistant genes found in wastewater samples from a South African city

3 months / medicalxpress


Financing rush: IPOs and venture cash fueling obesity drug race

Colorado biotech Ambrosia lands $100M for oral GLP-1

3 months / endpoints / Kyle LaHucik

Employer telehealth company eMed raises $200M at $2B valuation

3 months / fiercehealthcare

Kailera Plans IPO for Obesity Drug That Could Top Lilly’s Zepbound

3 months / medcitynews / Frank Vinluan

Kailera plans IPO for Phase 3 obesity drug from Hengrui

3 months / endpoints / Kyle LaHucik


New commercial models: subscriptions, telehealth, expanded patient access

Novo Nordisk launches discounted subscription program for Wegovy through telehealth providers

3 months / fiercehealthcare

Weight-loss jabs will be offered on NHS for people at risk of further heart attacks

3 months / bbc

A new way to sell weight loss drugs?

3 months / endpoints / Lydia Ramsey Pflanzer

Novo Nordisk launches subscription program for Wegovy drugs

3 months / endpoints / Shelby Livingston


Regulatory wins and science shaping next-generation weight-loss drugs

FDA approves new weight loss pill in record time

3 months / medicalxpress

Eli Lilly Gets Speedy FDA Nod for Oral GLP-1 Drug, a Competitor to New Novo Nordisk Pill

3 months / medcitynews / Frank Vinluan

FDA approves Eli Lilly’s GLP-1 pill for weight loss

3 months / beckershospitalreview / Paige Twenter

New insights into weight-loss hormones: How FGF21 works in the brain

3 months / medicalxpress

FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity

3 months / medicalxpress

Lilly wins approval of anti-obesity pill orforglipron, setting up new battle with Novo

3 months / endpoints / Elizabeth Cairns


All Other Stories

Eli Lilly’s oral GLP-1 now available at Amazon, GoodRx: 3 notes for hospitals

3 months / beckershospitalreview / Paige Twenter

Why weight-loss jabs work better for some people than others

3 months / bbc

Genes may predict GLP-1 weight loss: Study

3 months / beckershospitalreview / Ella Jeffries

AI scans 400,000 Reddit posts to flag overlooked GLP-1 side effects

3 months / medicalxpress

AI-based monitoring reveals protein deficiencies in people taking GLP-1 receptor agonists for weight loss

3 months / medicalxpress

Eli Lilly launches oral GLP-1 drug across US through Lilly Direct, telehealth providers

3 months / fiercehealthcare

Amazon Pharmacy adds Lilly GLP-1 pill with same-day delivery

3 months / beckershospitalreview / Ella Jeffries

Genetic predictors for GLP-1 weight loss efficacy and side effects identified

3 months / medicalxpress




Related Stories

Lilly’s next‑gen GLP‑1 posts compelling Phase 3 weight and A1C results / 3 months

Apitegromab preserves muscle while patients lose weight on GLP‑1s / 4 wks

Lilly’s triple‑agonist delivers over 28% weight loss in pivotal trial / 7 wks

Avalyn upsizes IPO to raise cash for lung drug trials / 2 months

Eli Lilly doubles down on AI drug discovery with Insilico deal / 3 months

Oricell raises tens of millions to expand CAR‑T efforts / 3 months

Neurocrine buys Soleno Therapeutics for $2.9B to gain Prader‑Willi drug / 3 months

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Diagnostics, Genetics, Medical Devices, Autism and look for the RSS link.




↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.